PHARMACOECONOMIC APPROACHES TO OPTIMIZING MEDICINE SUPPLY IN THE REPUBLIC OF KAZAKHSTAN

Аннотация

Medicine supply for the population is a key element of the healthcare system of the Republic of Kazakhstan.

Тип источника: Журналы
Годы охвата с 2021
inLibrary
Google Scholar
f
194
0

Скачивания

Данные скачивания пока недоступны.
Поделиться
Tursynbayeva , A., & Galiya , N. . (2025). PHARMACOECONOMIC APPROACHES TO OPTIMIZING MEDICINE SUPPLY IN THE REPUBLIC OF KAZAKHSTAN. Евразийский журнал академических исследований, 5(10(MPHAPP), 194. извлечено от https://inlibrary.uz/index.php/ejar/article/view/138336
0
Цитаты
Crossref
Сrossref
Scopus
Scopus

Аннотация

Medicine supply for the population is a key element of the healthcare system of the Republic of Kazakhstan.


background image

194

Volume 5, Issue 10: Special Issue
(EJAR)

ISSN: 2181-2020

MPHAPP

THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE

MODERN PHARMACEUTICS: ACTUAL

PROBLEMS AND PROSPECTS

TASHKENT, OCTOBER 17, 2025

in-academy.uz

PHARMACOECONOMIC APPROACHES TO OPTIMIZING MEDICINE SUPPLY IN

THE REPUBLIC OF KAZAKHSTAN

Tursynbayeva Ayazhan Berdalykyzy

Nurtayeva Galiya Kadyrkhanovna

Kazakh national medical university named by S. D.Asfendiyarov, Almaty city, Republic of

Kazakhstan

e-mail: ayazhan.berr@mail.ru,

nurtaeva.g@kaznmu.kz

https://doi.org/10.5281/zenodo.17332682

Relevance:

medicine supply for the population is a key element of the healthcare system of the

Republic of Kazakhstan. Under conditions of limited resources and rising drug prices, the importance
of rational use of budget funds increases. The application of pharmacoeconomic analysis methods
(cost-minimization, cost-effectiveness, cost-utility) makes it possible to compare costs and therapy
effectiveness, ensuring fair resource allocation and improved access to medicines.

Purpose of the study:

to study modern pharmacoeconomic methods and evaluate their

significance for optimizing medicine supply in the Republic of Kazakhstan.

Materials and methods:

a

review of the regulatory framework of the Republic of Kazakhstan

and the EAEU, as well as publications in Scopus, PubMed, and Web of Science databases from 2015
to 2025, was conducted. Data on the use of pharmacoeconomic methods in public procurement,
formulary systems, and clinical practice were analyzed.

Results:

the implementation of pharmacoeconomic approaches in the medicine supply system

of Kazakhstan allows reducing costs by 15–20% through the selection of the most evidence-based
drugs. The use of cost-effectiveness and cost-utility methods ensures comparability of costs and
clinical outcomes, which is important for the development of the National Drug Formulary and public
procurement. The application of pharmacoeconomic analysis in the development of clinical protocols
contributes to the integration of evidence-based medicine principles and increases system
transparency. The need to train specialists with competencies in pharmacoeconomics for practical
implementation of these methods has been highlighted.

Conclusions: pharmacoeconomics is an important tool for optimizing medicine supply in

Kazakhstan. A promising direction is the integration of economic evaluation into state healthcare
programs, training of specialists in pharmacoeconomic methods, and the development of local
research considering national specifics.